AU2016304737B2 - Methods of sedation and parenteral formulation for use during critical care treatment - Google Patents

Methods of sedation and parenteral formulation for use during critical care treatment Download PDF

Info

Publication number
AU2016304737B2
AU2016304737B2 AU2016304737A AU2016304737A AU2016304737B2 AU 2016304737 B2 AU2016304737 B2 AU 2016304737B2 AU 2016304737 A AU2016304737 A AU 2016304737A AU 2016304737 A AU2016304737 A AU 2016304737A AU 2016304737 B2 AU2016304737 B2 AU 2016304737B2
Authority
AU
Australia
Prior art keywords
gaboxadol
administered
patient
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2016304737A
Other languages
English (en)
Other versions
AU2016304737A1 (en
Inventor
Matthew During
Anna Kazanchyan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ovid Therapeutics Inc
Original Assignee
Ovid Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/834,027 external-priority patent/US9399034B1/en
Application filed by Ovid Therapeutics Inc filed Critical Ovid Therapeutics Inc
Priority claimed from PCT/US2016/045094 external-priority patent/WO2017027249A1/en
Publication of AU2016304737A1 publication Critical patent/AU2016304737A1/en
Application granted granted Critical
Publication of AU2016304737B2 publication Critical patent/AU2016304737B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Anesthesiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2016304737A 2015-08-11 2016-08-02 Methods of sedation and parenteral formulation for use during critical care treatment Ceased AU2016304737B2 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201562203748P 2015-08-11 2015-08-11
US201562203731P 2015-08-11 2015-08-11
US62/203,731 2015-08-11
US62/203,748 2015-08-11
US14/834,027 US9399034B1 (en) 2015-08-11 2015-08-24 Methods of sedation during critical care treatment
US14/834,027 2015-08-24
US15/185,650 2016-06-17
US15/185,650 US9717716B2 (en) 2015-08-11 2016-06-17 Methods of sedation during critical care treatment
PCT/US2016/045094 WO2017027249A1 (en) 2015-08-11 2016-08-02 Methods of sedation and parenteral formulation for use during critical care treatment

Publications (2)

Publication Number Publication Date
AU2016304737A1 AU2016304737A1 (en) 2018-02-22
AU2016304737B2 true AU2016304737B2 (en) 2021-03-11

Family

ID=59687449

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016304737A Ceased AU2016304737B2 (en) 2015-08-11 2016-08-02 Methods of sedation and parenteral formulation for use during critical care treatment

Country Status (12)

Country Link
US (1) US20180235942A1 (enExample)
EP (1) EP3334427A4 (enExample)
JP (1) JP6857647B2 (enExample)
KR (1) KR20180048707A (enExample)
CN (1) CN108135889A (enExample)
AU (1) AU2016304737B2 (enExample)
CA (1) CA2994952A1 (enExample)
CO (1) CO2018002534A2 (enExample)
IL (1) IL257296B2 (enExample)
MX (1) MX394213B (enExample)
PE (1) PE20181332A1 (enExample)
TW (1) TWI763632B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX391708B (es) 2015-07-17 2025-03-21 Ovid Therapeutics Inc Metodos para tratar trastornos del desarrollo con gaboxadol.
KR102518846B1 (ko) 2016-08-11 2023-04-05 오비드 테라퓨틱스 인크. 간질 장애의 치료를 위한 방법 및 조성물
US10071083B2 (en) 2017-02-03 2018-09-11 Ovid Therapeutics Inc Use of gaboxadol in the treatment of tinnitus
EP3833351A4 (en) 2018-09-20 2021-10-13 Ovid Therapeutics Inc. USE OF GABOXADOL FOR THE TREATMENT OF GILLES DE LA TOURETTE SYNDROME, TICS AND STATTING
BR112021009944A2 (pt) 2018-11-21 2021-08-17 Certego Therapeutics Inc. gaboxadol para reduzir risco de suicídio e alívio rápido de depressão
KR20210105387A (ko) 2018-12-17 2021-08-26 오비드 테라퓨틱스 인크. 비-24 시간 수면-각성 장애의 치료를 위한 가복사돌의 사용
JP2023526439A (ja) 2020-05-20 2023-06-21 セルテゴ セラピューティクス インコーポレイテッド 精神障害の処置のための環重水素化ガボキサドールおよびその使用
US20220218740A1 (en) * 2020-10-25 2022-07-14 Vaporworks Nursing Anesthesia Inc. Opioid-free compositions for anesthesiological applications and related methods and systems

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005063248A1 (en) * 2003-12-22 2005-07-14 Sepracor Inc. Modafinil combination therapy for improving sleep quality

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6071933A (en) * 1999-12-03 2000-06-06 Diversified Medical Innovations, Inc. Homogeneous remifentanil-propofol blend for patient controlled anesthesia and process for its use
ATE454140T1 (de) * 2004-02-18 2010-01-15 Sepracor Inc Dopamin-agonisten-kombinationstherapie mit sedativa zur verbesserung der schlafqualität
US20090143335A1 (en) * 2007-10-29 2009-06-04 H. Lundbeck A/S Modified absorption formulation of gaboxadol
US9399034B1 (en) * 2015-08-11 2016-07-26 Ovid Therapeutics Inc Methods of sedation during critical care treatment

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005063248A1 (en) * 2003-12-22 2005-07-14 Sepracor Inc. Modafinil combination therapy for improving sleep quality

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Cheng et al., Anesthesiology (1985), vol. 63(2)pp. 147-151. *
PANDHARIPANDE PRATIK ET AL, "Narcotic-based sedation regimens for critically ill mechanically ventilated patients", CRITICAL CARE (2005) Vol. 9, No. 3, pages 247 - 248, DOI:10.1186/CC3523 *
PIERSON, R., "Merck, Lundbeck scrap insomnia drug after trials", Reuters, 29 March 2007, <URL:https://www.reuters.com/article/businesspro-merck-lundbeck-gaboxadol-dc-idUSN2828549020070328> *
VALENTIN N ET AL, "RESPIRATORY EFFECT OF THIP, A GABA-AGONISTIC ANALGESIC, DURING HALOTHANE ANAESTHESIA", ACTA ANAESTHESIOLOGICA SCANDINAV (1983), vol. 27, no. 5, pages 366 - 368 *

Also Published As

Publication number Publication date
JP6857647B2 (ja) 2021-04-14
IL257296A (en) 2018-03-29
EP3334427A4 (en) 2019-02-06
US20180235942A1 (en) 2018-08-23
CA2994952A1 (en) 2017-02-16
CN108135889A (zh) 2018-06-08
IL257296B (en) 2022-10-01
CO2018002534A2 (es) 2018-05-31
TW201717944A (zh) 2017-06-01
AU2016304737A1 (en) 2018-02-22
KR20180048707A (ko) 2018-05-10
MX2018001720A (es) 2018-09-06
TWI763632B (zh) 2022-05-11
MX394213B (es) 2025-03-24
PE20181332A1 (es) 2018-08-20
EP3334427A1 (en) 2018-06-20
JP2018522920A (ja) 2018-08-16
IL257296B2 (en) 2023-02-01

Similar Documents

Publication Publication Date Title
AU2016304737B2 (en) Methods of sedation and parenteral formulation for use during critical care treatment
US11806336B2 (en) Methods and compositions for treatment of epileptic disorders
US10111865B2 (en) Methods of sedation during critical care treatment
US20210379028A1 (en) Treatment of depressive disorders
WO2017027249A1 (en) Methods of sedation and parenteral formulation for use during critical care treatment
US20220110917A1 (en) Use of gaboxadol, ganaxolone and allopregnanolone to treat movement disorders
HK1256349A1 (en) Methods of sedation and parenteral formulation for use during critical care treatment
HK40027257A (en) Treatment of depressive disorders

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired